<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01425788</url>
  </required_header>
  <id_info>
    <org_study_id>OS-G-01</org_study_id>
    <nct_id>NCT01425788</nct_id>
  </id_info>
  <brief_title>Comparison of Different Up-dosing Schedules With Osiris Phleum Pratense</brief_title>
  <acronym>Osiris</acronym>
  <official_title>Comparison of Different Up-dosing Schedules With Osiris Phleum Pratense</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ALK-Abelló A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ergomed</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>ACM Pivotal Global Central Laboratory</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Brecon Pharmaceuticals Ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>ALK-Abelló A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to investigate the tolerability of Osiris Phleum pratense used
      with 2 simplified up-dosing schedules compared to the up-dosing schedule used in current
      practice.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tolerability based on reporting of adverse events</measure>
    <time_frame>An average of 42 days per subject</time_frame>
    <description>Recording of adverse events are performed during the entire trial period, from screening to final follow-up contact.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subject satisfaction</measure>
    <time_frame>Measured at &quot;End of treatment/end of trial Visit&quot;</time_frame>
    <description>To compare the subjects' satisfaction of the different dosing schedules at end of the trial (after 30 days of treatment with trial medication).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">236</enrollment>
  <condition>Rhino-conjunctivitis</condition>
  <arm_group>
    <arm_group_label>Osiris Phleum pratense - Group A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group A up-dosing schedule from 1IR (index of Reactivity) /day to 240 IR/day in 11 days and thereafter 300 IR/day in 19 days.
Day 1-6: 1,2,4,6,8,10 IR/day Day 7-11: 30, 60, 120, 180, 240 IR/day Day 12-30: 300 IR/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Osiris Phleum pratense - Group B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group B Up-dosing schedule:
Day 1-5: 50 IR/day Day 6-10: 150 IR/day Day 11-30: 300 IR/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Osiris Phleum pratense - Group C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group C up-dosing schedule:
Day 1-10: 50 IR/day Day 11-20: 150 IR/day Day 21-30: 300 IR/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Osiris Phleum pratense</intervention_name>
    <arm_group_label>Osiris Phleum pratense - Group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Osiris Phleum pratense</intervention_name>
    <arm_group_label>Osiris Phleum pratense - Group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Osiris Phleum pratense</intervention_name>
    <arm_group_label>Osiris Phleum pratense - Group C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent obtained before entering the trial

          -  Male or female &gt;/= 18 years at visit 1

          -  A clinically relevant history of grass pollen induced allergic rhinoconjunctivitis
             (moderate to severe) and having received symptomatic treatment during grass pollen
             season 2010 and 2011

          -  Positive skin prick test response (wheal diameter &gt;/= 3mm) to Phleum pratense

          -  Positive specific IgE against Phleum pratense (&gt;/= 0,70KUL / class 2)

          -  Female subjects of childbearing potential must have a negative pregnancy test and be
             willing to practice appropriate contraceptive methods until Visit 4

          -  Subjects willing and able to comply with trial protocol regimen

        Exclusion Criteria:

          -  Subjects included in another protocol (treatment intervention and/or investigational
             medicine product) or having participated in another clinical trial within 30 days
             prior to visit 1

          -  A clinically relevant history of symptomatic seasonal allergic rhinoconjunctivitis
             caused by an allergen (e.g. hazel, alder, birch, ash) to which the subject will be
             exposed during the 30-day treatment period.

          -  A clinically relevant medical history of symptomatic perennial allergy to allergen(s)
             to which the subject is regularly exposed (e.g. cat, house dust mites).

          -  Known sensitization (history of positive SPT) to food allergens with oral allergy
             syndrome

          -  Uncontrolled asthma (in accordance with GINA guidelines) within the last 12 months

          -  FEV &lt; 60% of predicted within the last 12 months

          -  Severe asthma exacerbation(s) within the last 12 months

          -  A clinically relevant chronic disease (&gt;/= 3 months) (e.g fibrosis, malignancy, type 1
             diabetes mellitus, malabsorption or malnutrition, renal or hepatic insufficiency)

          -  Malignancy or systemic disease affecting the immune system (e.g. autoimmune disease,
             immune complex disease or immune deficiency disease)

          -  Inflammatory conditions in the oral cavity with severe symptoms such as oral lichen
             planus with ulcerations or severe oral mycosis or dental extraction at randomisation

          -  Medical history of recurrent urticaria or atopic dermatitis during the last 2 years

          -  Currently receiving treatment preventing the initiation of SIT (e.g. tricyclic
             antidepressants, mono amine oxidase inhibitors (MAOIs) and catechol-O-methyl
             transferase inhibitors (COMT inhibitors))

          -  History of allergy, hypersensitivity, or intolerance to the excipients of the
             investigational medicinal product

          -  Being immediate family of the investigator or trial staff, defined as the
             investigator's / staff's spouse, parent, grandparent, child or grandchild

          -  History of drug induced (incl. immunotherapy) facial angioedema (including experience
             of Quincke oedema) or a family (parents or siblings) history of hereditary angioedema

          -  Anticipated use of any prohibited medication within the specified time windows as
             defined in the protocol

          -  Previous treatment by immunotherapy with grass pollen for more than one month within
             the last 5 years

          -  Any clinically significant condition or situation, other than the condition being
             studied, that in the opinion of the investigator would interfere with the trial
             evaluations or optimal participation

          -  History of anaphylaxis with cardio respiratory symptoms (e.g. food allergy, drugs or
             an idiopathic reaction)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Piotr Kuna, Prof.med</last_name>
    <role>Principal Investigator</role>
    <affiliation>Uniwersytecki Szpital Kliniczny Nr1, Lodz, Poland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Poradnia Alergologii i Chorob Pluc Uniwersyteckiego Szpitala Klinicznego Nr1 im. N. Barlickiego w Lodzi</name>
      <address>
        <city>Lodz</city>
        <zip>90-153</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 26, 2011</study_first_submitted>
  <study_first_submitted_qc>August 29, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 30, 2011</study_first_posted>
  <last_update_submitted>June 25, 2015</last_update_submitted>
  <last_update_submitted_qc>June 25, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 26, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Grass pollen induced allergic rhinoconjunctivitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Conjunctivitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

